Influences on pathologic complete response in breast cancer patients after neoadjuvant chemotherapy.
Carolin MuellerGilda SchmidtIngolf Juhasz-BössLisa JungSarah HuwerErich-Franz SolomayerStephanie Juhasz-BössPublished in: Archives of gynecology and obstetrics (2021)
Particularly patients with high risk cancer and patients, participating in clinical trials benefit most from chemotherapy. Therefore, breast cancer patients can be encouraged to participate in clinical trials for chemotherapy.
Keyphrases
- neoadjuvant chemotherapy
- locally advanced
- clinical trial
- rectal cancer
- end stage renal disease
- squamous cell carcinoma
- radiation therapy
- sentinel lymph node
- lymph node
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- papillary thyroid
- randomized controlled trial
- squamous cell
- chemotherapy induced
- patient reported